“If you're stuck and sitting in a pitch-black room, desperately hoping for a door that leads you outside, even a brief flash of light can give you hope that the door exists—even if the light fades immediately. (...) That moment of light makes a huge difference, because it gives you a reason to keep searching for the door.”

- EPIsoDE study participant

We participated in the EPIsoDE phase-II study, the (at the time) largest government-funded psychedelic trial in the world – and the first modern clinical study with psychedelics in Germany ever. The results from the study are currently being published in high-ranking journals. This trial focused on the safety and efficacy of psilocybin for treatment-resistant depression.

Building on this data, we are now the lead partner for a crucial Phase III study – the DiMension Trial. This will be the first study of its kind uniquely designed to achieve public health care reimbursement with more than 700 participants. What sets this trial apart is its unique design: testing psychedelic therapy directly against the current standard of care. This approach is indispensable for integrating psilocybin therapy into public health care, allowing for reimbursement, and making these treatments truly accessible to those in need.

Why Psilocybin?

Psilocybin has the best-to-date preclinical and clinical data available. Patent protection has long ceased, and our non-profit approach will ensure that once approved the therapy will be easily accessible to everyone in need.
 
The second reason is that psilocybin’s safety data for medical use is excellent.

Thus, psilocybin is the best candidate to lead to a safe, effective and accessible therapy.

“The APT course, I would say is really, a gift to yourself. To yourself at a personal level and at a professional level, but even more a gift for you client that you try to help with severe mental health issues.”

- Jessica Soolsma, Psychiatrist, APT participant

We believe that successful implementation of psychedelic therapies requires more than just regulatory and legal frameworks – it demands a robust network of trained therapists equipped with the skills and ethics to deliver these therapies to those who need them most. To achieve this, we offer a range of practical educational courses focused on psychedelic therapies and mental health.

Augmented Psychotherapy Training (APT)

Our flagship program, the 15-month Augmented Psychotherapy Training (APT) course, is designed for psychiatrists, psychotherapists, and other mental health professionals. This comprehensive course equips participants with the knowledge and skills to conduct psychedelic therapies safely and effectively, awarding 74 CME points upon completion.

Other educational programs 

Our public communication involves the media, those interested in psychedelic experience themselves and the general public. Besides the APT course, we also offer the online Molecules course on the science of psychoactive drugs, the Footsteps online-course on psychedelic integrations, as well as our 4-day in-person workshop on integrating psychedelic experiences, Beyond Experience.